Form 4: Poseida Therapeutics Executive Chairman Reports Stock Transactions
SEC Form 4 Filing
Executive Chairman Mark J. Gergen of Poseida Therapeutics reports the withholding of shares for tax obligations and acquisition of shares through the employee stock purchase plan.
Summary
- Mark J. Gergen, Executive Chairman of Poseida Therapeutics, filed a Form 4 disclosing changes in beneficial ownership of company stock.
- On January 2, 2025, 23,313 shares were withheld to cover income tax obligations related to the vesting of restricted stock units granted on January 2, 2024.
- Also on January 2, 2025, Gergen acquired 2,748 shares through the company's 2020 Employee Stock Purchase Plan (ESPP).
- Following these transactions, Gergen beneficially owns 630,726 shares of Poseida Therapeutics common stock.
Sentiment
Score: 7
Explanation: The document reflects routine transactions and is neutral in sentiment. It is a standard regulatory filing.
Positives
- The acquisition of shares through the ESPP indicates the Executive Chairman's participation in the company's employee stock purchase program.
- The reported transactions are a normal part of executive compensation and stock ownership.
Industry Context
This filing is a routine disclosure of stock transactions by a company executive, which is common in publicly traded companies. It reflects standard practices for executive compensation and stock ownership.
Comparison to Industry Standards
- The use of restricted stock units and employee stock purchase plans are standard compensation practices in the biotechnology industry.
- The reporting of stock transactions via Form 4 is a standard regulatory requirement for company insiders.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they are related to executive compensation and do not represent a significant change in ownership.
Key Dates
| Date | Description |
|---|---|
| 01/02/2024 | Date of grant of Restricted Stock Unit Awards to the Reporting Person. |
| 01/02/2025 | Date of stock transactions including tax withholding and ESPP purchase. |
| 01/03/2025 | Date of filing of the Form 4. |
Keywords
Form 4, Poseida Therapeutics, Stock Transactions, Beneficial Ownership, Executive Chairman, Employee Stock Purchase Plan, Restricted Stock Units, Tax Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.